| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes LA Carey, EC Dees, L Sawyer, L Gatti, DT Moore, F Collichio, DW Ollila, ... Clinical cancer research 13 (8), 2329-2334, 2007 | 2794 | 2007 |
| Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 379 (2), 111-121, 2018 | 2029 | 2018 |
| Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study R Nanda, LQM Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ... Journal of Clinical oncology 34 (21), 2460, 2016 | 1516 | 2016 |
| Prospective validation of a 21-gene expression assay in breast cancer JA Sparano, RJ Gray, DF Makower, KI Pritchard, KS Albain, DF Hayes, ... New England Journal of Medicine 373 (21), 2005-2014, 2015 | 1503 | 2015 |
| Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in … HA Burris III, HI Hurwitz, EC Dees, A Dowlati, KL Blackwell, B O'Neil, ... Journal of clinical oncology 23 (23), 5305-5313, 2005 | 804 | 2005 |
| The proteasome as a target for cancer therapy PM Voorhees, EC Dees, B O’Neil, RZ Orlowski Clinical cancer research 9 (17), 6316-6325, 2003 | 586 | 2003 |
| Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies NL Spector, W Xia, H Burris III, H Hurwitz, EC Dees, A Dowlati, B O'Neil, ... Journal of clinical oncology 23 (11), 2502-2512, 2005 | 481 | 2005 |
| Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer JA Sparano, RJ Gray, PM Ravdin, DF Makower, KI Pritchard, KS Albain, ... New England journal of medicine 380 (25), 2395-2405, 2019 | 434 | 2019 |
| Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies RZ Orlowski, PM Voorhees, RA Garcia, MD Hall, FJ Kudrik, T Allred, ... Blood 105 (8), 3058-3065, 2005 | 403 | 2005 |
| The interaction of post‐traumatic growth and post‐traumatic stress symptoms in predicting depressive symptoms and quality of life EF Morrill, NT Brewer, SC O'Neill, SE Lillie, EC Dees, LA Carey, BK Rimer Psycho‐Oncology: Journal of the Psychological, Social and Behavioral …, 2008 | 388 | 2008 |
| Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and … B Melichar, A Adenis, AC Lockhart, J Bennouna, EC Dees, O Kayaleh, ... The Lancet Oncology 16 (4), 395-405, 2015 | 275 | 2015 |
| American joint committee on cancer tumor–node–metastasis stage after neoadjuvant chemotherapy and breast cancer outcome LA Carey, R Metzger, EC Dees, F Collichio, CI Sartor, DW Ollila, ... Journal of the National Cancer Institute 97 (15), 1137-1142, 2005 | 249 | 2005 |
| Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study WJ Irvin Jr, CM Walko, KE Weck, JG Ibrahim, WK Chiu, EC Dees, ... Journal of clinical oncology 29 (24), 3232, 2011 | 220 | 2011 |
| Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301 AA Miller, DJ Murry, K Owzar, DR Hollis, EB Kennedy, G Abou-Alfa, ... Journal of Clinical Oncology 27 (11), 1800, 2009 | 220 | 2009 |
| A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer EC Dees, S O'reilly, SN Goodman, S Sartorius, MA Levine, RJ Jones, ... Cancer investigation 18 (6), 521-529, 2000 | 210 | 2000 |
| Risk perceptions and psychosocial outcomes of women with ductal carcinoma in situ: longitudinal results from a cohort study A Partridge, K Adloff, E Blood, EC Dees, C Kaelin, M Golshan, J Ligibel, ... Journal of the National Cancer Institute 100 (4), 243-251, 2008 | 198 | 2008 |
| Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors JR Infante, EC Dees, AJ Olszanski, SV Dhuria, S Sen, S Cameron, ... Journal of clinical oncology 32 (28), 3103-3110, 2014 | 192 | 2014 |
| Phase I study of aurora A kinase inhibitor MLN8237 in advanced solid tumors: safety, pharmacokinetics, pharmacodynamics, and bioavailability of two oral formulations EC Dees, RB Cohen, M von Mehren, TE Stinchcombe, H Liu, ... Clinical cancer research 18 (17), 4775-4784, 2012 | 181 | 2012 |
| A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors HH Soliman, E Jackson, T Neuger, EC Dees, RD Harvey, H Han, ... Oncotarget 5 (18), 8136, 2014 | 177 | 2014 |
| The role of the ubiquitination-proteasome pathway in breast cancer: applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer RZ Orlowski, EC Dees Breast Cancer Research 5, 1-7, 2002 | 174 | 2002 |
